Atrial Fibrillation Surgery Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Atrial Fibrillation Surgery Market is expected to register a CAGR of nearly 12.2% during the forecast period.
The COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failures, including myocarditis and rhythm disturbance. The data from Wuhan, China, has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID-19. Furthermore, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.
Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Healthcare providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimizing the risk of exposure to COVID-19. The article 'Home Monitoring of Cardiac Devices in the Era of COVID-19', published in 2020, concluded that new technologies and digital platforms to aid in remote care should be developed and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of the studied market.
The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality across the globe, and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly.
Atrial Fibrillation (AFib) is the most prevalent chronic arrhythmia in patients above 65 years of age. As per the Centers for Disease Control and Prevention (CDC) estimates, around 12.1 million people in the United States will have AFib by 2030. With the growth in the aging population, this number is expected to increase. Thus, the increasing incidences of CVD and atrial fibrillation are expected to augment the growth of the market studied and are posing a high burden on the economies of various countries due to the high cost of treatment. Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period.
Scope of the Report
As per the scope of the report, atrial fibrillation (AF) is a common abnormal heart rhythm that occurs when electrical impulses fire off from different places in the atria in a disorganized way.
The atrial fibrillation surgery market is segmented by product (catheter ablation and surgical ablation), end user (hospitals, ambulatory surgical centers, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.
|By End User|
|Ambulatory Surgical Centers|
|Other End Users|
Key Market Trends
The Ambulatory Surgical Center Segment is Expected to Witness Good Growth over the Forecast Period
The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.
In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.
Owing to the COVID-19 situation, it was observed that obesity had increased. According to an article published by the European Journal of Nutrition in December 2020, the rate of obesity increased globally. The major reasons include a change in lifestyle and a decreased physical activity among people. This increase in the obesity population is expected to drive the studied market in the near future.
To understand key trends, Download Sample Report
North America is the Largest Growing Segment over the Forecast Period
The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in 2017, around 2.7 to 6.1 million people in the United States had AFib, and with the rising geriatric population, it is expected that the demand for the studied market will grow in the future. As per American Heart Association (2018), high blood pressure was one of the leading causes of atrial fibrillation that accounted for approximately 14-22% of all AFib cases in the United States.
With the presence of key players in the country, technological advancements and the availability of favorable insurance policies are augmenting the growth of the market studied in the United States. For instance, in July 2020, Boston Scientific Corporation announced that it received the US FDA approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.
To understand geography trends, Download Sample Report
The market for atrial fibrillation consists of local as well as global companies, which are focusing on the development of new product launches and also witnessing the penetration of new entrants in the market. In May 2020, CardioFocus Inc. announced that the US Food and Drug Administration (FDA) approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This system offers a new level of speed, control, and predictability for physicians, which makes it an ideal tool for AFib ablation. Thus, owing to the technological advancements and the focus on improving the healthcare system, it is expected that more companies will enter the market that may further drive the market growth in the future.
- In March 2021, Tempus announced that the US FDA granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter.
- In February 2021, Medtronic received approval from the Food and Drug Administration (FDA) for DiamondTemp Ablation (DTA) system, which treats patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF), and who have been unresponsive to drug therapy. The DiamondTemp system is a temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Obesity and Heart Diseases
4.2.2 Rising Number of Programs to Enhance Public Awareness
4.3 Market Restraints
4.3.1 High Cost of Procedure
4.3.2 Regulatory Issues Associated with the Devices
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 Catheter Ablation
5.1.2 Surgical Ablation
5.2 By End User
5.2.2 Ambulatory Surgical Centers
5.2.3 Other End Users
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
5.3.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Boston Scientific Corporation
6.1.2 Medtronic PLC
6.1.3 Biotronik SE & Co. KG
6.1.4 AtriCure Inc.
6.1.5 Cardiofocus Inc.
6.1.6 Abbott Laboratories
6.1.7 Advansta Inc.
6.1.8 Johnson & Johnson
6.1.9 MicroPort Scientific Corporation
6.1.10 Koninklijke Philips NV
6.1.11 Siemens AG
6.1.12 Osypka AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Atrial Fibrillation Surgery Market market is studied from 2018 - 2026.
What is the growth rate of Global Atrial Fibrillation Surgery Market?
The Global Atrial Fibrillation Surgery Market is growing at a CAGR of 12.2% over the next 5 years.
Which region has highest growth rate in Global Atrial Fibrillation Surgery Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Atrial Fibrillation Surgery Market?
North America holds highest share in 2020.
Who are the key players in Global Atrial Fibrillation Surgery Market?
Boston Scientific Corporation, Medtronic Plc, Biotronik, AtriCure, Inc., Cardiofocus, Inc. are the major companies operating in Global Atrial Fibrillation Surgery Market.